A Phase 1 interventional study of Treatment A: BGF MDI HFO and Treatment B: BGF MDI HFA in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 111th largest by enrollment of the 194 interventional ones that give a count, is one of 10 that started in 2022, is one of 42 in phase 1, and was the 243rd registered.
5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in France
Ages 18–99
AstraZeneca · Sites in India
Ages 18+
AstraZeneca · Sites in Argentina, Egypt, Mexico and 4 more countries
Ages 18+
AstraZeneca · Sites in Argentina, Colombia, Egypt and 9 more countries
Ages 30–80
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 57 · Phase 3 77 · Phase 4 19
First in 1999; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is above the median of 62 across 3,844 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 137 across the 194 interventional studies, 976 across the 89 observational. Of the 264 that completed or were terminated, 127 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
9 of the studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07315958AstraZenecaStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics | 2027-04-30 |
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
| NCT07307781AstraZenecaStudy of Patient With Frequent Exacerbations in Moscow | 2027-06-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will evaluate bioequivalence, pharmacokinetics, safety, and tolerability of Budesonide, Glycopyrronium and Formoterol (BGF) metered dose inhaler (MDI) formulated with hydrofluoroolefin (HFO) [Test] and hydrofluoroalkane (HFA) [Reference] in healthy participants (male or female).
This is a Phase I, randomized, double-blind, single-dose, single-center, partial-replicate, 3 way cross-over study to assess pharmacokinetic and safety of BGF MDI when administered with different propellants, HFO (HFO-1234ze) - test and HFA (HFA-134a) - reference.
The study will comprise of:
Each participant will receive 3 single dose treatments of BGF MDI (Treatment A: BGF MDI HFO [Test]; Treatment B: BGF MDI HFA [Reference]) following an overnight fast of at least 8 hours on Day 1 of each treatment period.
The reference formulation will be administered during 2 of the 3 treatment periods.
There will be a minimum of a 3 to 7 day washout between administration of each treatment.
Each participant will be involved in the study for approximately 55 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Test formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.
Drug: Treatment A: BGF MDI HFO · Drug: Treatment B: BGF MDI HFA
Participants will receive Reference formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.
Drug: Treatment A: BGF MDI HFO · Drug: Treatment B: BGF MDI HFA
Participants will receive 4 oral inhalations as a single dose - test formulation; administered during 1 treatment period.
Also known as: Budesonide/Glycopyronium/Formoterol fumarate pressurized inhalation suspension, HFO
Participants will receive 4 oral inhalations as a single dose - reference formulation; administered during 2 treatment periods.
Also known as: Budesonide/Glycopyronium/Formoterol fumarate pressurized inhalation suspension, HFA
Area Under Plasma Concentration-time Curve From Zero to Infinity (AUCinf)
The AUCinf of budesonide, glycopryrronium and formoterol in participants was evaluated.
Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Area Under the Plasma Concentration-curve From Zero to the Last Quantifiable Concentration (AUClast)
The AUClast of budesonide, glycopryrronium and formoterol in participants was evaluated.
Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Maximum Observed Plasma (Peak) Drug Concentration (Cmax)
The Cmax of budesonide, glycopryrronium and formoterol in participants was evaluated.
Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Time to Reach Peak or Maximum Observed Concentration or Response Following Drug Administration (Tmax)
The tmax of budesonide, glycopryrronium and formoterol in participants was evaluated.
Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Terminal Rate Constant, Estimated by Log-linear Least Squares Regression of the Terminal Part of the Concentration-time Curve (λz)
The λz of budesonide, glycopryrronium and formoterol in participants was evaluated.
Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz)
The t½λz of budesonide, glycopryrronium and formoterol in participants was evaluated.
Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRTinf)
The MRTinf of budesonide, glycopryrronium and formoterol in participants was evaluated.
Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F)
The CL/F of budesonide, glycopryrronium and formoterol in participants was evaluated.
Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Volume of Distribution (Apparent) at Steady State Following Extravascular Administration (Based on Terminal Phase) (Vz/F)
The Vz/F of budesonide, glycopryrronium and formoterol in participants was evaluated.
Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
The safety and tolerability of single doses of BGF MDI HFO and BGF MDI HFA was evaluated in healthy participants.
Time frame: From Screening up to Follow-up (3 to 7 days post final dose) [approximately 55 days]
This study was conducted in one study center in the US.
| Milestone | Treatment Sequence ABB | Treatment Sequence BAB | Treatment Sequence BBA |
|---|---|---|---|
| Started | 36 | 36 | 36 |
| Completed | 35 | 36 | 36 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
The AUCinf of budesonide, glycopryrronium and formoterol in participants was evaluated.
| hour*picogram/milliliter (h*pg/mL) | Treatment A | Treatment B (Replicate 1) | Treatment B (Replicate 2) |
|---|---|---|---|
| Budesonide | 4047 ± 46.71 | 4112 ± 40.78 | 4012 ± 46.01 |
| Glycopyronium | 85.62 ± 94.55 | 81.10 ± 78.85 | 120.9 ± 83.40 |
| Formoterol | 124.3 ± 43.80 | 121.3 ± 41.19 | 125.0 ± 40.55 |
The AUClast of budesonide, glycopryrronium and formoterol in participants was evaluated.
| h*pg/mL | Treatment A | Treatment B (Replicate 1) | Treatment B (Replicate 2) |
|---|---|---|---|
| Budesonide | 3943 ± 47.60 | 4003 ± 40.66 | 3905 ± 46.82 |
| Glycopyrronium | 52.68 ± 52.68 | 49.31 ± 84.38 | 63.29 ± 72.90 |
| Formoterol | 102.5 ± 48.47 | 100.3 ± 45.89 | 103.9 ± 42.47 |
The Cmax of budesonide, glycopryrronium and formoterol in participants was evaluated.
| picograms per milliliter (pg/mL) | Treatment A | Treatment B (Replicate 1) | Treatment B (Replicate 2) |
|---|---|---|---|
| Budesonide | 1124 ± 65.67 | 1143 ± 60.79 | 1146 ± 65.91 |
| Glycopyrronium | 17.09 ± 90.52 | 20.41 ± 87.46 | 19.70 ± 87.52 |
| Formoterol | 23.48 ± 60.12 | 24.54 ± 62.22 | 26.12 ± 54.39 |
The tmax of budesonide, glycopryrronium and formoterol in participants was evaluated.
| Hours | Treatment A | Treatment B (Replicate 1) | Treatment B (Replicate 2) |
|---|---|---|---|
| Budesonide | 0.35 (0.08 to 2.00) | 0.33 (0.08 to 2.02) | 0.33 (0.07 to 2.05) |
| Glycopyrronium | 0.03 (0.02 to 4.13) | 0.03 (0.03 to 2.02) | 0.03 (0.02 to 4.02) |
| Formoterol | 0.08 (0.03 to 4.02) | 0.08 (0.03 to 2.03) | 0.08 (0.03 to 2.12) |
The λz of budesonide, glycopryrronium and formoterol in participants was evaluated.
| 1/hour | Treatment A | Treatment B (Replicate 1) | Treatment B (Replicate 2) |
|---|---|---|---|
| Budesonide | 0.1508 ± 25.19 | 0.1538 ± 25.24 | 0.1500 ± 24.99 |
| Glycopyrronium | 0.05906 ± 97.13 | 0.06010 ± 92.16 | 0.03853 ± 100.5 |
| Formoterol | 0.08911 ± 36.39 | 0.08926 ± 36.50 | 0.08625 ± 39.39 |
The t½λz of budesonide, glycopryrronium and formoterol in participants was evaluated.
| Hours | Treatment A | Treatment B (Replicate 1) | Treatment B (Replicate 2) |
|---|---|---|---|
| Budesonide | 4.596 ± 25.19 | 4.506 ± 25.24 | 4.622 ± 24.99 |
| Glycopyrronium | 11.74 ± 97.13 | 11.53 ± 92.16 | 17.99 ± 100.5 |
| Formoterol | 7.779 ± 36.39 | 7.766 ± 36.50 | 8.037 ± 39.39 |
The MRTinf of budesonide, glycopryrronium and formoterol in participants was evaluated.
| Hours | Treatment A | Treatment B (Replicate 1) | Treatment B (Replicate 2) |
|---|---|---|---|
| Budesonide | 4.855 ± 21.37 | 4.893 ± 24.30 | 4.924 ± 19.98 |
| Glycopyrronium | 16.02 ± 93.66 | 15.56 ± 86.14 | 24.50 ± 96.84 |
| Formoterol | 10.48 ± 29.28 | 10.38 ± 30.42 | 10.62 ± 33.34 |
The CL/F of budesonide, glycopryrronium and formoterol in participants was evaluated.
| Liters/hour (L/h) | Treatment A | Treatment B (Replicate 1) | Treatment B (Replicate 2) |
|---|---|---|---|
| Budesonide | 158.2 ± 46.71 | 155.6 ± 40.78 | 159.5 ± 46.01 |
| Glycopyrronium | 336.4 ± 94.55 | 355.1 ± 78.85 | 238.2 ± 83.40 |
| Formoterol | 154.5 ± 43.80 | 158.2 ± 41.19 | 153.6 ± 40.55 |
The Vz/F of budesonide, glycopryrronium and formoterol in participants was evaluated.
| Liters (L) | Treatment A | Treatment B (Replicate 1) | Treatment B (Replicate 2) |
|---|---|---|---|
| Budesonide | 1049 ± 47.84 | 1012 ± 39.18 | 1064 ± 45.06 |
| Glycopyrronium | 5695 ± 43.16 | 5908 ± 46.44 | 6182 ± 44.59 |
| Formoterol | 1734 ± 32.78 | 1773 ± 33.69 | 1782 ± 36.52 |
The safety and tolerability of single doses of BGF MDI HFO and BGF MDI HFA was evaluated in healthy participants.
| Participants | Treatment A | Treatment B (Replicate 1) | Treatment B (Replicate 2) |
|---|---|---|---|
| Any AEs | 16 | 21 | 9 |
| Any SAE | 0 | 0 | 0 |
| Any SAE with outcome of death | 0 | 0 | 0 |
| Any AE leading to discontinuation of Investigational Product (IP) | 0 | 0 | 0 |
| Any possibly related AE | 10 | 12 | 4 |
| Any possibly related SAE | 0 | 0 | 0 |
Collected over From Screening up to Follow-up Phone call (3 to 7 days post final dose) [approximately 55 days]. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 0/108 (0%) | 0/108 (0%) | 16/108 (14.8%) |
| Treatment B (Replicate 1) | 0/107 (0%) | 0/107 (0%) | 21/107 (19.6%) |
| Treatment B (Replicate 2) | 0/107 (0%) | 0/107 (0%) | 9/107 (8.4%) |
| Event | Treatment A | Treatment B (Replicate 1) | Treatment B (Replicate 2) |
|---|---|---|---|
| HeadacheNervous system disorders | 4/108 | 8/107 | 1/107 |
| ConstipationGastrointestinal disorders | 0/108 | 2/107 | 0/107 |
| Back painMusculoskeletal and connective tissue disorders | 1/108 | 2/107 | 0/107 |
| Catheter site painGeneral disorders | 0/108 | 1/107 | 2/107 |
| Catheter site swellingGeneral disorders | 0/108 | 0/107 | 2/107 |
| DizzinessNervous system disorders | 2/108 | 1/107 | 1/107 |
| Catheter site bruiseGeneral disorders | 2/108 | 1/107 | 1/107 |
| PharyngitisInfections and infestations | 0/108 | 1/107 | 0/107 |
| Upper respiratory tract infectionInfections and infestations | 0/108 | 0/107 | 1/107 |
| AnxietyPsychiatric disorders | 0/108 | 1/107 | 1/107 |
The randomized analysis set consisted of all participants randomized into the study.
| Age, Continuous(Years) | Treatment Sequence ABB | Treatment Sequence BAB | Treatment Sequence BBA | Total |
|---|---|---|---|---|
| Mean | 36.0 ± 10.0 | 35.8 ± 9.6 | 39.5 ± 11.2 | 37.1 ± 10.3 |
| Sex: Female, Male(Participants) | Treatment Sequence ABB | Treatment Sequence BAB | Treatment Sequence BBA | Total |
|---|---|---|---|---|
| Female | 14 | 19 | 16 | 49 |
| Male | 22 | 17 | 20 | 59 |
| Race/Ethnicity, Customized(Participants) | Treatment Sequence ABB | Treatment Sequence BAB | Treatment Sequence BBA | Total |
|---|---|---|---|---|
| White | 21 | 19 | 20 | 60 |
| Black or African American | 8 | 8 | 10 | 26 |
| Asian | 4 | 3 | 2 | 9 |
| Other | 3 | 6 | 4 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Oct 2022 to primary completion in Apr 2023, 6 months.
Results were first posted in Apr 2025, 2 years after primary completion.
Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 6 months is above that.
Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →